
Opinion|Videos|August 27, 2026
Learning From Real-World Experience With Axatilimab
Zahra Mahmoudjafari, PharmD, BCOP, FHOPA, MBA, discusses how axatilimab performs in actual practice versus what AGAVE-201 predicted, including responses in organ manifestations not well-represented in the trial and how real-world monitoring protocols have evolved based on accumulated clinical experience.
Advertisement
Episodes in this series

Zahra Mahmoudjafari, PharmD, BCOP, FHOPA, MBA, discusses how axatilimab performs in actual practice versus what AGAVE-201 predicted, including responses in organ manifestations not well-represented in the trial and how real-world monitoring protocols have evolved based on accumulated clinical experience.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves First-in-Class Daraxonrasib for Metastatic Pancreatic Cancer
2
FDA Grants Fast Track Designation to CK0803 for Amyotrophic Lateral Sclerosis
3
What Pharmacists Should Know About Novo Nordisk-Eli Lilly GLP-1 Ad Suit
4
Yeast-Based Universal Flu Vaccine Fully Protects Mice Against 3 Influenza Strains
5































































































